cisplatin / Generic mfg. - LARVOL DELTA

Subcutaneous versus intravenous toripalimab, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic non-squamous (nsq) non-small cell lung cancer (NSCLC): A randomized phase III trial (ELCC 2026) - P3 | "Methods Patients with histologically or cytologically confirmed recurrent or metastatic nsqNSCLC without EGFR-sensitive mutations or ALK fusions were randomized (1:1) to receive either SC toripalimab (360 mg) or IV toripalimab (240 mg) every 3 weeks plus pemetrexed (500 mg/m 2 ) and carboplatin (area under the curve [AUC] = 5) or cisplatin (75 mg/m 2 ) for up to 4 cycles. Legal entity responsible for the study Shanghai Junshi Biosciences. Funding Shanghai Junshi Biosciences."

Clinical • Combination therapy • IO biomarker • Metastases • P3 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. (PubMed, Cancer) - "The MSKD is feasible in patients with PDAC and, although not powered for definitive outcomes, shows trends in improved PFS and OS when combined with gemcitabine, nab-paclitaxel, and cisplatin, without added toxicity or detriment to QOL. Larger studies are required to confirm these findings and establish the value of the MSKD in pancreatic cancer treatment."

Clinical • Journal • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

The Efficacy & Tolerability of Imiquimod, 5-Fluorouracil, Photodynamic Therapy, and Chemotherapy in Comparison to Surgical Approaches for Treatment of Extramammary Paget’s Disease (EMPD): A Literature Review (AAD 2026) - "Chemotherapy, primarily low-dose 5-FU plus cisplatin or taxane-based regimens, provided modest disease control and may serve as palliative or neoadjuvant options in advanced or unresectable EMPD. Our review highlights that while surgical approaches remain most effective for durable remission, nonsurgical therapies offer viable alternatives for noninvasive EMPD and patients unable to tolerate surgery. Future multicenter studies with larger cohorts are necessary to establish standardized treatment algorithms and to validate the role of combination nonsurgical regimens in reducing recurrence and improving quality of life."

Clinical • Review • Rare Diseases

Comprehensive Evaluation of Risk Factors Associated with Ifosfamide-Induced Encephalopathy: A Real-World Retrospective Review (HOPA 2026) - "Several studies have identified risk factors associated with the development of IIE including hypoalbuminemia, increased serum creatinine, increased hemoglobin, poor performance status, prior cisplatin exposure, disease in the pelvis, ifosfamide infusion time, obesity, concomitant use of CYP3A4 or CYP2B6 inhibitors, cancer type, ifosfamide dose, ifosfamide formulation, and age...Secondary endpoints will include identifying an association between concomitant fosaprepitant/aprepitant use and IIE as well as comparing the incidence of neurotoxicity between the solution formulation of ifosfamide and reconstituted powder formulation... Pending Conclusion/ Pending"

Real-world • Real-world evidence • Retrospective data • Review • CNS Disorders • Genetic Disorders • Germ Cell Tumors • Hematological Malignancies • Lymphoma • Obesity • Sarcoma • Solid Tumor • CYP3A4

Real-World Comparison of a Modified versus Standard Durvalumab plus Gemcitabine and Cisplatin Regimen in Advanced Biliary Tract Cancers (HOPA 2026) - "Despite an increased rate of treatment modifications with the standard 21-day regimen, RDI remained lower with the modified 28-day regimen. Further conclusions and discussion are pending completion of final analyses."

Clinical • Metastases • Real-world • Real-world evidence • Ampulla of Vater Carcinoma • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

Incidence of Acute Kidney Injury with Low-Dose Cisplatin Alone Versus Low-Dose Cisplatin with Mannitol (HOPA 2026) - "Pending"

Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Renal Disease

Retrospective Review of Bleomycin Pulmonary Toxicity and Correlation with Serial PFTs and Symptoms (HOPA 2026) - "Bleomycin, etoposide, and cisplatin (BEP) is the standard treatment regimen for most patients, however, cumulative bleomycin exposure can lead to significant pulmonary toxicity.1-8 Bleomycin-induced lung injury ranges from asymptomatic pulmonary function test abnormalities to life-threatening interstitial lung disease (ILD).1-8 Although serial diffusing capacity of the lungs for carbon monoxide (DLCO) monitoring can detect early toxicity, there is no consensus regarding monitoring frequency or a DLCO decline threshold for treatment modification.1-8 This can lead to inconsistencies surrounding drug discontinuation potentially causing inappropriate or unnecessary discontinuation while increasing the risk for delayed recognition of toxicity. At the time of abstract submission, data collection and analysis are ongoing. Results and conclusions will be presented at the time of poster presentation."

Retrospective data • Review • Genito-urinary Cancer • Germ Cell Tumors • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Testicular Cancer

Evaluation of D-PACE (and variations) Chemotherapy in the Management of Relapsed/Refractory Myeloma at a Tertiary Cancer Center in the era of CAR-T Cell Therapies (HOPA 2026) - "Background : In patients with relapsed/refractory multiple myeloma, D-PACE (dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide) is a combination regimen historically used as salvage therapy. in progress References: British Journal of Haematology, 2013, 161: 802-810.J Hematol Oncol. 2019; 12(1):120."

CAR T-Cell Therapy • Hematological Malignancies • Multiple Myeloma • Oncology

Evaluating outcomes of a high-dose cisplatin rate change protocol at a local Veterans Affairs facility (HOPA 2026) - "Results pending."

Clinical • Acute Kidney Injury • Bladder Cancer • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Lung Cancer • Nephrology • Renal Disease • Small Cell Lung Cancer • Solid Tumor

Optimization of Electrolyte Administration in Patients Receiving Cisplatin: A Comparative Study of Scheduled Versus As Needed Supplementation (HOPA 2026) - "Assess chair time savings/additional smart pump needs associated with PRN versus scheduled electrolyte administration Methodology: This multi-clinics, single center, retrospective chart review evaluated patients who received cisplatin with electrolyte supplementation at Baptist Cancer Center outpatient infusion clinics between January 1, 2021 and December 31, 2023, with eligible patients identified through the electronic medical record. Results Result Pending Discussion/conclusion Result Pending"

Clinical • Solid Tumor

REDUCE-30: Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=31 | Not yet recruiting | Sponsor: Sara Medek

New P2 trial • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: The First Hospital of Jilin University

New trial • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Multitargeting Pt(IV) Anticancer Prodrugs Bearing Mono- and Bis-Probenecid Ligands in Axial Positions: Synthesis and Evaluation of Biological Activity. (PubMed, Pharmaceuticals (Basel)) - "Background: To battle the side effects of anticancer Pt(II) drug cisplatin, the development of photoactivatable and/or intracellular reduction-activatable Pt(IV) prodrugs has become a promising strategy. The direct conjugation of probenecid to the axial positions of oxoplatin confers the resulting Pt(IV) prodrugs a multitargeting property, significantly promoting the cytotoxicity of the resulting Pt(IV) complexes. This finding provides a practical strategy for drug design and cancer treatment based on platinum complexes."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma. (PubMed, Pharmaceutics) - " Cytotoxic assays on MG-63 OS cells revealed potent activity with an IC50 of 0.50 ± 0.04 µM, significantly surpassing its free ligand (IC50 = 13.9 ± 1.6 µM) and cisplatin (IC50 = 39.0 ± 1.8 µM)...In a xenograft model, sustained administration of Cu4L4 (2 mg/kg, i.p., twice weekly) inhibited tumor growth by 43.6%, reduced mitotic index, and increased necrotic area without significant systemic toxicity. Overall, Cu4L4 displayed potent and selective antitumor activity against OS cells in 2D, 3D, and in vivo models, underscoring copper-hydrazone complexes as promising scaffolds for the development of new therapies against OS."

Journal • Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Synthesis and Development of 3-((2,4-Difluorophenyl)Amino)Propanoic Acid Derivatives as an Antiproliferative Medicinal Chemistry Scaffold Targeting Growth Factor Receptors. (PubMed, Pharmaceuticals (Basel)) - "Active compounds also demonstrated cytotoxic effects in HEK293 cells comparable to those of doxorubicin and cisplatin. These results identify 3-[(2,4-difluorophenyl)amino]propanoic acid derivatives, particularly compound 9, as promising scaffolds for further structural optimization toward the development of kinase-targeting antiproliferative agents."

Journal • Oncology • HER-2 • MET

Potential Mechanisms of MAP Kinase JNK's Involvement in Modulating Cancer Cell Fate in a Cisplatin Concentration-Dependent Manner. (PubMed, Pharmaceuticals (Basel)) - "In the case of cisplatin + JNK inhibitor SP600125, DNA damage and reactive oxygen species (ROS) contribute to cell death regulation in different ways. As a result, AKT phosphorylation and function are altered. The findings emphasize the importance of assessing the role of drug concentration when combining them with JNK inhibition when monitoring therapeutic efficacy and toxicity issues in personalized cancer treatment."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

RNA modification control of platinum sensitivity via ADAM23-dependent pathway (AACR 2026) - "We assessed m⁶A and METTL3 expression after cisplatin treatment using RT-qPCR and western blotting...Further analysis using SRAMP identified several very high confidence m6A modification sites on ADAM23 mRNA in human. These findings suggest that METTL3-mediated m⁶A modifications, through regulation of ADAM23, may represent a novel therapeutic target in ovarian cancer."

Brain Cancer • Glioma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • METTL3

Survival outcomes with concurrent systemic therapy in patients with a medical contraindication to cisplatin in the non-operative management of locally advanced HNSCC, an NCDB Study (AACR 2026) - "Standard-of-care non-operative management for locally advanced head & neck squamous cell carcinoma (HNSCC) is definitive radiation with concurrent cisplatin. Critically, early survival benefits seen with concurrent chemotherapy dissipate with long-term follow-up possibly due to deaths from other causes in this population with extensive co-morbidity. Further prospective study is needed to evaluate the benefit of concurrent chemotherapy over cetuximab in this frail population."

Clinical • Metastases • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Cancer chemotherapy-induced accelerated aging is mitigated by activation of the altruistic stem cell defense response (AACR 2026) - "We hypothesized that the Altruistic Stem Cell (ASC) Defense (ASD) response (1) of mesenchymal stem cells (MSCs) represents protective pathway against chemotherapy and tumor-induced ABA at both systemic and tumor-microenvironment (TME) levels. A cisplatin-induced accelerated aging mouse model (2) was used to evaluate whether activation of the ASD response mitigates ABA... Chemotherapy accelerates aging in circulating progenitors and in tumor-derived CD271⁺ MSCs, creating an aging TME that may foster tumor progression. Clinically, ASD can be quantified from PBMC-derived MSCs and may serve as a biomarker to stratify patients at highest risk of ABA.References:1. Pathak L, et al PMID: 33887214.2."

Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • NGFR • PTPRC

Dissecting the spatial architecture of plasmacytoid urothelial carcinoma to inform therapeutic strategies (AACR 2026) - "Patients with PUC have worse response to cisplatin-based neoadjuvant chemotherapy and worse outcomes than patients with CUC, emphasizing the importance of therapeutic development...Using spatial transcriptomics at single cell resolution, this study delineates PUC architecture and demonstrates the interplay between E-cadherin loss, EMT, and macrophage activation. Further characterization of PUC-specific expression and TME components will identify potential therapeutic vulnerabilities."

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • CDH1 • VIM

Mechanistic insights into reactive oxygen species (ROS) homeostasis in ovarian cancer chemoresistance (AACR 2026) - "Pharmacologic inhibition was performed using GSI-MK0752 (NOTCH1/HES1) and CYT387 (JAK2/STAT5). A ROS-responsive NOTCH1/HES1 and IL11/STAT5 signaling axis plays a central role in maintaining CSC populations and promoting platinum resistance in ovarian cancer. Dual targeting of these signaling pathways disrupts the redox-regulated circuit and enhances cisplatin efficacy, supporting further investigation of this combinatorial strategy as a potential therapeutic approach for platinum-resistant ovarian cancer."

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • CD44 • HES1 • JAK2 • NOTCH1 • SOD2 • STAT5

Utilizing confocal live-cell imaging for evaluating therapeutic efficacy and toxicity in complex oncology models (AACR 2026) - "Spheroid formation was monitored for 3 days, then the effects of camptothecin (0.3 - 10 µM) or cisplatin (3 - 100 µM) were tested...Additionally, following immune-mediated tumor killing, we observed a density-depending increase in green area with PBMCs expansion. Taken together, these data highlight the ability of multiparameter, multiplane confocal live cell analysis to provide clear, rapid insights from a variety of complex pre-clinical models, including immuno-oncology and organoid-based toxicity readouts."

Clinical • Oncology • Solid Tumor • PTPRC

Drug screening using patient-derived tumoroids harboring diverse mutations to identify effective therapeutics for metastatic cancer patients (AACR 2026) - "Tumoroids were treated with five chemotherapeutic agents—Cisplatin, Doxorubicin, Oxaliplatin, Fluorouracil, and Cetuximab—at six concentrations over a 7-day period (three doses). Notably, Doxorubicin, previously unused in these patients, demonstrated significant activity—highlighting the assay's potential to identify drugs for precision therapy and enable patient-specific drug ranking. In summary, scalable PDPT expansion combined with physiologically relevant assay systems offers a cost-effective, predictive, and non-animal approach for metastatic cancer drug screening, advancing the concept of precision medicine."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • CK19 • KRT19 • VIM

Tumor treating fields (TTFields) enhance chemotherapy-induced proteotoxic stress in pancreatic cancer cells (AACR 2026) - P1/2 | "TTFields along with gemcitabine, nab-paclitaxel, and cisplatin (the Triple regimen) is under clinical investigation (NCT04605913) and may enhance antitumor efficacy by overwhelming the tumor's proteostasis mechanisms. Collectively, these findings suggest that TTFields potentiate the antiproliferative effects of the Triple chemotherapy by amplifying UPR signaling through the IRE1α/XBP1 and PERK/eIF2 pathways. These results provide mechanistic insight into how TTFields may enhance the efficacy of chemotherapy in pancreatic cancer and support further clinical evaluation of this concomitant treatment approach."

Oncology • Pancreatic Cancer • Solid Tumor • HSPA5 • XBP1

Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial. (PubMed, Lancet) - "IMPT and IMRT had similar late physical quality of life scores, gastrostomy-tube dependence, local control, and overall survival. In health-care settings where IMPT is not used routinely for oropharyngeal squamous cell carcinoma, IMRT remains the standard of care."

Journal • P3 data • Acute Kidney Injury • Cardiovascular • Head and Neck Cancer • Nephrology • Oncology • Oropharyngeal Cancer • Renal Disease • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck